Biogen Idec (BIIB) PLEGRIDY Met Primary Endpoint in Phase 3 ADVANCE
Tweet Send to a Friend
Biogen Idec, Inc. (Nasdaq: BIIB) announced the positive, full first-year results from its two-year pivotal Phase 3 ADVANCE study of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
